309 related articles for article (PubMed ID: 15157247)
1. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.
Franchini M; Gandini G; Veneri D; de Matteis G; Federici F; Solero P; Aprili G
Transfusion; 2004 Jun; 44(6):833-7. PubMed ID: 15157247
[TBL] [Abstract][Full Text] [Related]
2. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.
Hicken BL; Tucker DC; Barton JC
Am J Gastroenterol; 2003 Sep; 98(9):2072-7. PubMed ID: 14499790
[TBL] [Abstract][Full Text] [Related]
3. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.
Muncunill J; Vaquer P; Galmés A; Obrador A; Parera M; Bargay J; Besalduch J
J Clin Apher; 2002; 17(2):88-92. PubMed ID: 12210712
[TBL] [Abstract][Full Text] [Related]
4. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
[TBL] [Abstract][Full Text] [Related]
5. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.
Butt NM; Clark RE
Bone Marrow Transplant; 2003 Nov; 32(9):909-13. PubMed ID: 14561992
[TBL] [Abstract][Full Text] [Related]
6. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.
Casanova-Esteban P; Guiral N; Andrés E; Gonzalvo C; Mateo-Gallego R; Giraldo P; Paramo JA; Civeira F
Metabolism; 2011 Jun; 60(6):830-4. PubMed ID: 20846699
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
[TBL] [Abstract][Full Text] [Related]
8. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.
Panch SR; Yau YY; West K; Diggs K; Sweigart T; Leitman SF
Transfusion; 2015 Mar; 55(3):611-22. PubMed ID: 25209879
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.
Majhail NS; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):832-7. PubMed ID: 20079863
[TBL] [Abstract][Full Text] [Related]
10. [Long-term survival of 2 cases of hemochromatosis respectively homozygous for His63Asp and Cys282Tyr mutations].
Samii K; Darbellay R; Trachsel H; Beris P
Schweiz Med Wochenschr; 1997 Nov; 127(45):1867-70. PubMed ID: 9446207
[TBL] [Abstract][Full Text] [Related]
11. [Hemochromatosis--from an underdiagnosed curiosity to a common disease].
Hagve TA; Asberg A; Ulvik R; Borch-Iohnsen B; Thorstensen K
Tidsskr Nor Laegeforen; 2009 Apr; 129(9):863-6. PubMed ID: 19415085
[TBL] [Abstract][Full Text] [Related]
12. Iron overload in hematopoietic cell transplantation.
Majhail NS; Lazarus HM; Burns LJ
Bone Marrow Transplant; 2008 Jun; 41(12):997-1003. PubMed ID: 18438425
[TBL] [Abstract][Full Text] [Related]
13. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Greenway A; Ware RE; Thornburg CD
Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
[TBL] [Abstract][Full Text] [Related]
14. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements.
Olynyk JK; Luxon BA; Britton RS; Bacon BR
Am J Gastroenterol; 1998 Mar; 93(3):346-50. PubMed ID: 9517637
[TBL] [Abstract][Full Text] [Related]
15. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
16. Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: a case-control study.
Kom GD; Schwedhelm E; Nielsen P; Böger RH
Free Radic Biol Med; 2006 Apr; 40(7):1194-200. PubMed ID: 16545687
[TBL] [Abstract][Full Text] [Related]
17. Soluble transferrin receptor in hemochromatosis patients during phlebotomy therapy.
Piéroni L; Mekhloufi F; Thiolières JM; Hainque B; Herson S; Jardel C
Clin Chim Acta; 2005 Mar; 353(1-2):61-6. PubMed ID: 15698591
[TBL] [Abstract][Full Text] [Related]
18. Iron overload and toxicity: the hidden risk of multiple blood transfusions.
Shander A; Cappellini MD; Goodnough LT
Vox Sang; 2009 Oct; 97(3):185-97. PubMed ID: 19663936
[TBL] [Abstract][Full Text] [Related]
19. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
Kowdley KV; Modi NB; Peltekian K; Vierling JM; Ferris C; Valone FH; Gupta S
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1118-1128. PubMed ID: 37863080
[TBL] [Abstract][Full Text] [Related]
20. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.
Valenti L; Fracanzani AL; Dongiovanni P; Bugianesi E; Marchesini G; Manzini P; Vanni E; Fargion S
Am J Gastroenterol; 2007 Jun; 102(6):1251-8. PubMed ID: 17391316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
